Screening wants throughput, consistency and low cost per well. Primary human cells offer none of those and offer relevance instead. The productive question is not which is better but where in a campaign the switch should happen, and that decision is usually made too late, after a series has already been optimised against a cell line that does not resemble the eventual target.
What lines give up
| Immortalised lines | Primary immune cells | |
|---|---|---|
| Consistency | High, clonal | Donor-dependent |
| Throughput | High | Constrained by material and handling |
| Genetic background | One | As many as you include donors |
| Receptor and signalling fidelity | Altered by immortalisation and culture adaptation | Representative |
| Population inference | None available | Direct, if enough donors are used |
The receptor fidelity row is the one that bites. Immortalisation and long culture adaptation change expression and signalling, so a compound optimised against a line may have been optimised against a receptor context that does not exist in patients.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
Where the switch belongs
A defensible sequence runs lines for primary screening, primary cells from a small donor set for hit confirmation, and a wider donor panel for lead characterization. The common failure is deferring primary cells until lead optimisation is complete, at which point a series has been shaped by a background it will never encounter again.
Confirming on primary cells earlier costs more per data point and less per program.
Designing around donor variability
Donor variation is not a defect to be minimized. It is a preview of what the compound will meet in a population, and a compound that works in three donors and fails in two has told you something important that a cell line could not.
Practically that means using several donors from the start of primary-cell work rather than one, running them separately, reporting per donor, and treating a bimodal response as a finding to investigate rather than an outlier to exclude. Pooling defeats the purpose entirely, for reasons set out in single-donor versus pooled.
Assay windows are narrower
Primary cells have a limited functional lifespan ex vivo, they need a rest period after thaw before functional work, and they respond to handling in ways lines do not. Each of those compresses the window in which an assay produces meaningful data.
Automation designed for lines often assumes robustness that primary cells do not have, so plate handling, incubation times and reagent addition steps usually need revisiting rather than porting. Thaw handling specifically is covered in thawing PBMCs.
Supply is a design constraint
A screening campaign consumes material predictably, and running out of a donor mid-series means the remaining compounds are tested against a different background. Securing enough material from the same donors before the campaign starts, or an arrangement that allows returning to them, is a design decision rather than a procurement one.
OrganaBio documents cryopreserved PBMCs and isolated T, NK, B and monocyte populations from a single donor program, with repeat collection available for eligible donors. Recurring supply is covered in standing orders and recurring supply.
Frequently asked questions
Why screen on primary immune cells rather than cell lines?
Because immortalisation and culture adaptation alter receptor expression and signalling, so a compound optimised against a line may have been optimised against a context that does not exist in patients. Primary cells also allow inference about a population rather than one genetic background.
When should a campaign move from lines to primary cells?
A defensible sequence uses lines for primary screening, primary cells from a small donor set for hit confirmation, and a wider panel for lead characterization. Deferring primary cells until optimisation is complete means the series was shaped by a background it will not encounter again.
Is donor variability a problem in screening?
It is information. A compound that works in three donors and fails in two has revealed something a cell line could not. Bimodal responses are findings to investigate rather than outliers to exclude.
Should donors be pooled to reduce screening variability?
No. Pooling hides the variation that is the reason for using primary cells, and pooling immune cells additionally introduces allogeneic reactivity between donors that is unrelated to the compound.
Why hold the donor panel constant across a compound series?
Because comparing analogues across different donors compares chemistry and donor together. Using the same panel throughout is what makes a structure-activity relationship interpretable.
Do screening protocols transfer directly from lines to primary cells?
Rarely. Primary cells have a limited ex vivo functional lifespan, need a rest period after thaw and respond to handling in ways lines do not, so plate handling, incubation times and reagent steps usually need revisiting.
How does material supply affect screening design?
Running out of a donor mid-campaign means remaining compounds are tested against a different background. Securing sufficient material from the same donors up front, or an arrangement permitting return to them, is a design decision rather than a procurement one.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
